Early-stage trial finds stem cell therapy for retinitis pigmentosa is safe

A team of UC Davis Health researchers has shown that CD34+ stem cells can be safely administered into retinitis pigmentosa (RP) patients’ eyes and may offer therapeutic benefits. The phase 1 trial also confirmed that these specialized cells can be readily isolated from the patient’s own bone marrow. The study was published in the journal Ophthalmology Science.

Facebook Comments